The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and empathy in a clinical setting and is designed for single participants and those in partnerships.
Adult healthy volunteers aged 18 years and above
Matched for age, sex, BMI, and menopause/hormonal contraceptives to patients
No medication, except hormonal contraception
At least mild impairment in sexual function and satisfaction, defined as an ASEX-score ≥10 points and an NSSS-S score ≤ 48 points
Pregnancy and breastfeeding within the last eight weeks
Participation in a trial with investigational drugs within 30 days
Active substance use disorder within the last six months
Consumption of alcoholic beverages >15 drinks/week